$32.92
1.05% day before yesterday
Nasdaq, Oct 24, 10:00 pm CET
ISIN
US55910K1088
Symbol
DNTH

Magenta Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Magenta Therapeutics Inc Classifications & Recommendation:

Buy
95%
Hold
5%

Magenta Therapeutics Inc Price Target

Target Price $65.28
Price $32.92
Potential
Number of Estimates 12
12 Analysts have issued a price target Magenta Therapeutics Inc 2026 . The average Magenta Therapeutics Inc target price is $65.28. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 19 analysts: 18 Analysts recommend Magenta Therapeutics Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Magenta Therapeutics Inc stock has an average upside potential 2026 of . Most analysts recommend the Magenta Therapeutics Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 6.24 2.41
120.49% 61.44%
Net Margin -1,361.70% -4,631.59%
11.53% 240.13%

13 Analysts have issued a sales forecast Magenta Therapeutics Inc 2025 . The average Magenta Therapeutics Inc sales estimate is

$2.4m
Unlock
. This is
50.39% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$5.3m 8.85%
Unlock
, the lowest is
$1.3m 72.60%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $6.2m 120.49%
2025
$2.4m 61.44%
Unlock
2026
$2.2m 10.52%
Unlock
2027
$2.8m 32.05%
Unlock
2028
$38.2m 1,244.25%
Unlock
2029
$192m 401.37%
Unlock
2030
$530m 176.42%
Unlock
2031
$806m 52.19%
Unlock
2032
$1.0b 27.78%
Unlock

15 Magenta Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Magenta Therapeutics Inc net profit estimate is

$-111m
Unlock
. This is
2.88% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-103m 9.90%
Unlock
, the lowest is
$-121m 5.25%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-85.0m 95.06%
2025
$-111m 31.15%
Unlock
2026
$-116m 4.39%
Unlock
2027
$-126m 8.31%
Unlock
2028
$-111m 12.21%
Unlock
2029
$-130m 17.20%
Unlock
2030
$45.0m 134.69%
Unlock

Net Margin

2024 -1,361.70% 11.53%
2025
-4,631.59% 240.13%
Unlock
2026
-5,403.27% 16.66%
Unlock
2027
-4,431.99% 17.98%
Unlock
2028
-289.44% 93.47%
Unlock
2029
-67.67% 76.62%
Unlock
2030
8.49% 112.55%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -2.55 -3.46
69.82% 35.69%
P/E negative
EV/Sales 437.81

15 Analysts have issued a Magenta Therapeutics Inc forecast for earnings per share. The average Magenta Therapeutics Inc EPS is

$-3.46
Unlock
. This is
8.13% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-3.21 0.31%
Unlock
, the lowest is
$-3.75 17.19%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-2.55 69.82%
2025
$-3.46 35.69%
Unlock
2026
$-3.62 4.62%
Unlock
2027
$-3.92 8.29%
Unlock
2028
$-3.44 12.24%
Unlock
2029
$-4.03 17.15%
Unlock
2030
$1.40 134.74%
Unlock

P/E ratio

Current -10.29 30.94%
2025
-9.51 7.56%
Unlock
2026
-9.11 4.21%
Unlock
2027
-8.41 7.68%
Unlock
2028
-9.58 13.91%
Unlock
2029
-8.17 14.72%
Unlock
2030
23.56 388.37%
Unlock

Based on analysts' sales estimates for 2025, the Magenta Therapeutics Inc stock is valued at an EV/Sales of

437.81
Unlock
and an P/S ratio of
544.78
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 217.19 103.92%
2025
437.81 101.58%
Unlock
2026
489.25 11.75%
Unlock
2027
370.51 24.27%
Unlock
2028
27.56 92.56%
Unlock
2029
5.50 80.05%
Unlock
2030
1.99 63.82%
Unlock
2031
1.31 34.29%
Unlock
2032
1.02 21.74%
Unlock

P/S ratio

Current 270.26 70.12%
2025
544.78 101.58%
Unlock
2026
608.80 11.75%
Unlock
2027
461.04 24.27%
Unlock
2028
34.30 92.56%
Unlock
2029
6.84 80.05%
Unlock
2030
2.47 63.82%
Unlock
2031
1.63 34.29%
Unlock
2032
1.27 21.74%
Unlock

Current Magenta Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Truist Securities
Locked
Locked
Locked Oct 14 2025
Clear Street
Locked
Locked
Locked Sep 17 2025
Stifel
Locked
Locked
Locked Sep 12 2025
Wedbush
Locked
Locked
Locked Sep 12 2025
Guggenheim
Locked
Locked
Locked Sep 09 2025
Raymond James
Locked
Locked
Locked Sep 09 2025
Baird
Locked
Locked
Locked Sep 09 2025
Analyst Rating Date
Locked
Truist Securities:
Locked
Locked
Oct 14 2025
Locked
Clear Street:
Locked
Locked
Sep 17 2025
Locked
Stifel:
Locked
Locked
Sep 12 2025
Locked
Wedbush:
Locked
Locked
Sep 12 2025
Locked
Guggenheim:
Locked
Locked
Sep 09 2025
Locked
Raymond James:
Locked
Locked
Sep 09 2025
Locked
Baird:
Locked
Locked
Sep 09 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today